Product Categories
| Country: | China |
|---|---|
| Tel: | |
| Mobile: | 15002134094 |
| E-mail: | marketing@targetmol.cn |
| QQ: | 2881954871 |
| Skype: | Chat Now! |
| Product Name | MF | CAS | Details |
|---|
| Cibisatamab | 1855925-27-7 | Details |
| Zilovertamab | 1643432-38-5 | Details |
| Brentuximab | 2088770-90-3 | Details |
| Inotuzumab | 1660159-36-3 | Details |
| Sonepcizumab | 1031360-18-5 | Details |
| GSNKGAIIGLM(131602-53-4(free base)) | C45H81N13O14S | Details |
| HDAC-IN-57 | C21H19N3O4 | 2716217-79-5 | Details |
| MoTPS1-IN-1 | C23H27F3N2O4 | 2991072-02-5 | Details |
| TV 3279 | C16H20N2O2 | 209394-29-6 | Details |
| Theralizumab | 906068-56-2 | Details |
| Clivatuzumab | 1622075-09-5 | Details |
| Ordesekimab | 879293-15-9 | Details |
| DSPE-NHS | C49H89N2O13P | 1383932-86-2 | Details |
| PI3Kδ-IN-16 | C22H26N6O2 | 2766437-35-6 | Details |
| Trontinemab | 2568868-35-7 | Details |
| Zharp2-1 | C19H18N3O2PS | 2772600-18-5 | Details |
| Ogremorphin | C21H17N3OS | 352563-21-4 | Details |
| h-NTPDase-IN-3 | C16H10N4S | 2939933-10-3 | Details |
| RN-1665 | C20H24F5N3O3S2 | 1803003-65-7 | Details |
| A09-003 | C23H26N4O | 2911646-14-3 | Details |
| AC-099 hydrochloride | C9H9Cl2F3N4 | 849335-07-5 | Details |
| KSK94 | C25H26N4O | 2566716-07-0 | Details |
| KSK68 | C23H28N2O2 | 2566715-91-9 | Details |
| h-NTPDase-IN-2 | C19H16N4S | 2939933-03-4 | Details |
| Lingdolinurad | C17H12BrN3O2 | 2088176-96-7 | Details |
| Antimalarial agent 30 | C18H11F3N2 | 1597425-64-3 | Details |
| TIM-3-IN-2 | C25H23N3O6 | 1113126-49-0 | Details |
| PLpro/RBD-IN-1 | C13H10N4O | 1282451-83-5 | Details |
| DHX9-IN-2 | C18H16ClN3O3S2 | 2973395-71-8 | Details |
| EGFR/ErbB-2 inhibitor-1 | C23H15ClFN3OS2 | 1135150-79-6 | Details |
| HA5 | C15H10O5 | 2378406-17-6 | Details |
| LSD1-IN-27 | C24H25N3 | 2904571-94-2 | Details |
| SARS-CoV-2 3CLpro-IN-16 | C17H14N2OS | 352659-40-6 | Details |
| ADS032 | C22H29NO4S | 2757333-37-0 | Details |
| KSK67 | C22H27N3O2 | 2566715-93-1 | Details |
| Antiviral agent 34 | C29H33N3O2S | 945152-88-5 | Details |
| S5A1 | C27H33N3O4.ClH | 2055882-51-2 | Details |
| JG-2016 | C18H21ClN4O3 | 2887480-87-5 | Details |
| IDH2R140Q-IN-2 | C21H18F6N6O | 2749568-16-7 | Details |
| TIE-2/VEGFR-2 kinase-IN-5 | C21H13F6N5O2 | 1014407-83-0 | Details |
| EBOV-IN-1 | C34H43N3O5 | 1335113-30-8 | Details |
| Anti-inflammatory agent 51 | C22H22N6O6S | 2911610-03-0 | Details |
| Z16078526 | C18H17N3O4S | 852222-94-7 | Details |
| Aneratrigine hydrochloride | C19H20ClF2N5O2S2.ClH | 2097163-75-0 | Details |
| Usenamine A | C18H17NO6 | 1428417-60-0 | Details |
| VU534 | C21H22FN3O3S2 | 923509-20-0 | Details |
| FC-116 | C21H20FNO4 | 2417298-29-2 | Details |
| AKE-72 | C30H29F3N6O | 2566525-18-4 | Details |
| 1H-Indole, 3,3'-(2-thienylmethylene)bis[2-methyl- | C23H20N2S | 138801-72-6 | Details |
| SARS-CoV-2-IN-39 | C14H8ClF4NO3 | 2882823-03-0 | Details |
| BCAT-IN-4 | C19H14N2O4S | 406190-85-0 | Details |
| BCPA | C22H22Cl2N2O2 | 547731-67-9 | Details |
| CCG-13514 | C25H25BrN2O2 | 423741-32-6 | Details |
| A2B receptor antagonist 2 hydrochloride | C12H15N5.ClH | 724-70-9 | Details |
| B-Raf IN 16 | C20H19N5O3S | 2304746-24-3 | Details |
| TNF/IFNγ-IN-1 | C20H23N3O6 | 876013-29-5 | Details |
| KM02894 | C7H9N3OS2 | 116850-74-9 | Details |
| MMP-9-IN-6 | C25H19NO2 | 2241964-36-1 | Details |
| EGFR-IN-87 | C28H33N7O2 | 1835666-87-9 | Details |
| Topoisomerase II inhibitor 14 | C15H11Cl2N5 | 305343-00-4 | Details |
| Anti-inflammatory agent 49 | C21H22N8O3S | 851471-44-8 | Details |
| JHU 75528 | C23H21Cl2N5O2 | 947696-17-5 | Details |
| CpCDPK1/TgCDPK1-IN-1 | C18H17N5 | 1092788-23-2 | Details |
| P-gb-IN-1 | C30H28N2O6 | 2632874-49-6 | Details |
| Tubulin polymerization-IN-43 | C17H13F4N3O | 2773345-90-5 | Details |
| Tubulin polymerization-IN-55 | C22H24N2O4 | 2942396-29-2 | Details |
| AP-C2 | C18H16N4S | 682793-07-3 | Details |
| Aprocitentan | C16H14Br2N6O4S | 1103522-45-7 | Details |
| a-MSH, amide Acetate(581-05-5 free base) | C77H109N21O19S | Details |
| Nrf2 activator-3 | C23H18F3N3O2 | 2766570-23-2 | Details |
| MY-1076 | C29H33NO9 | 3008262-76-5 | Details |
| lorvotuzumab | 339306-30-8 | Details |
| D4R agonist-1 | C19H22N4S | 2826198-44-9 | Details |
| Enpp-1-IN-16 | C23H32N4O4 | 2289739-47-3 | Details |
| 17β-HSD10-IN-1 | C16H13ClN4O3S | 2316765-78-1 | Details |
| Ipamorelin 2 Pivalic acid | C38H49N9O5 | Details |
| Nurr1 agonist 2 | C18H14O3S | 742058-34-0 | Details |
| LW3 | C17H12F3N3O | 2803367-68-0 | Details |
| AST 7062601 | C18H15N3O4S | 675197-89-4 | Details |
| TNF-α-IN-9 | C17H14O4 | 2054199-25-4 | Details |
| IRG1-IN-1 | C18H15FO4 | 2407652-42-8 | Details |
| PAC1R antagonist 1 | C17H17ClN6O2 | 2305204-24-2 | Details |
| PLH1215 | 1332084-64-6 | Details |
| (1R,5S,6r)-N-(2-methyl-1-((3-methylpyridin-2-yl)oxy)propan-2-yl)-3-azabicyclo[3.1.0]hexane-6-carboxamide L(+)-Tartaric acid | C16H23N3O2.C4H6O6 | 2919211-45-1 | Details |
| XPW1 | C36H39ClFN7O2 | 2700286-66-2 | Details |
| ALK-IN-26 | C24H23NO3S | 2447607-85-2 | Details |
| AMPK activator 12 | C23H24BrNO2 | 431920-24-0 | Details |
| MyD88-IN-1 | C23H24N6O7S | 2911609-80-6 | Details |
| MC4033 | C16H13N3O3 | 28532-21-0 | Details |
| LFHP-1c | C55H64N6O4 | 2102347-47-5 | Details |
| DJ4 | C19H16N4OS | 1681020-24-5 | Details |
| Enfortumab | 1448664-46-7 | Details |
| Cbl-b-IN-5 | C17H17N5OS | 2368835-59-8 | Details |
| PLH2058 | 2525206-41-9 | Details |
| SARS-CoV-2-IN-38 | 2882823-27-8 | Details |
| Bivatuzumab | 214559-60-1 | Details |
| Tubulin inhibitor 32 | C18H19N3O3 | 2923531-39-7 | Details |
| QST4 | C16H13ClN4O2S2 | 2991427-35-9 | Details |
| Estrogen receptor antagonist 8 | 2889370-92-5 | Details |
| Phosphatase-IN-1 | C16H16Cl2FNO2 | 2889356-55-0 | Details |
| Product Total： Product Page： | ||||
| 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 | ||||